Nov 24, 2025 08:03AM Iterum Therapeutics expands ORLYNVAH distribution through McKesson

Nov 14, 2025 07:44AM Iterum Therapeutics Plc (ITRM) Misses Q3 EPS by 5c

Sep 19, 2025 08:00AM Iterum Therapeutics launches ORLYNVAH antibiotic in seven US states

Aug 20, 2025 08:00AM Iterum Therapeutics launches ORLYNVAH oral penem antibiotic in US

May 19, 2025 07:00AM Iterum Therapeutics Plc (ITRM) Announces Extension of Term of Promissory Note

May 13, 2025 05:58PM Iterum Therapeutics Plc (ITRM) Tops Q1 EPS by 5c

Apr 29, 2025 08:01AM Iterum Therapeutics Plc (ITRM) Announces $5 Million Registered Direct Offering of Ordinary Shares

Feb 7, 2025 07:21AM Iterum Therapeutics Plc (ITRM) Tops Q4 EPS by 10c

Nov 21, 2024 08:30AM Iterum Therapeutics Plc (ITRM) Regains Full Nasdaq Compliance

Oct 25, 2024 11:05AM Iterum Therapeutics Plc (ITRM) Receives U.S. FDA Approval of ORLYNVAH for the Treatment of Uncomplicated Urinary Tract Infections

Oct 25, 2024 10:56AM FDA approves new treatment for uncomplicated urinary tract infections in adult women who have limited or no alternative oral antibiotic treatment options (ITRM)

Oct 25, 2024 10:51AM Iterum Therapeutics Plc (ITRM) Halted, News Pending

Sep 10, 2024 07:01AM Iterum Therapeutics (ITRM) Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women

Sep 10, 2024 06:44AM H.C. Wainwright Reiterates Buy Rating on Iterum Therapeutics (ITRM)

Aug 15, 2024 06:42AM Iterum Therapeutics (ITRM) PT Lowered to $5 at H.C. Wainwright

Aug 14, 2024 07:10AM Iterum Therapeutics Plc (ITRM) Tops Q2 EPS by 15c

Aug 2, 2024 08:03AM Iterum Therapeutics (ITRM) Broadens Patent Estate for Oral Sulopenem

Jul 22, 2024 07:30AM Iterum Therapeutics (ITRM) Commences Rights Offering